XBiotech Inc
$ 2.30
-0.43%
16 Mar - close price
- Market Cap 70,427,000 USD
- Current Price $ 2.30
- High / Low $ 2.33 / 2.29
- Stock P/E N/A
- Book Value 4.60
- EPS -0.95
- Next Earning Report 2026-03-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.28 %
- 52 Week High 3.62
- 52 Week Low 2.09
About
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in Austin, Texas.
Analyst Target Price
$18.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-28 | 2025-08-29 | 2025-05-08 | 2025-03-13 | 2024-11-07 | 2024-08-12 | 2024-05-10 | 2024-03-15 | 2023-11-09 | 2023-08-11 | 2023-05-10 |
| Reported EPS | 0 | -0.2 | -0.06 | -0.357 | -0.3447 | -0.1646 | -0.427 | -0.3285 | -0.1523 | -0.2419 | -0.2872 | -0.13 |
| Estimated EPS | 0 | 0 | 0 | None | None | None | None | None | None | None | None | None |
| Surprise | 0 | -0.2 | -0.06 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $2.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIT
2026-03-14 07:51:49
XBiotech Inc. (NASDAQ:XBIT) stock has fallen below its two hundred-day moving average, trading at $2.31 as of Friday, March 14, 2026. The biopharmaceutical company, which last reported earnings on March 13th with an EPS of ($0.88), currently holds a "Sell" rating from analysts. Institutional investors have seen some activity, with firms like Persistent Asset Partners Ltd and Bank of America Corp DE adjusting their stakes in the company.
2026-03-13 18:51:49
XBiotech reported zero revenue for 2025, with no revenue expected in 2026, and a net loss of $(45.5) million, resulting in a diluted and basic net loss per share of $(1.49). The company maintained $125.6 million in cash, which is expected to support near-term development and facility preparation, despite a significant portion of operating expenses being allocated to R&D and leadership transition costs.
2026-03-13 18:51:49
XBiotech Inc. filed its annual report detailing its biopharmaceutical business, which focuses on True Human monoclonal antibodies, specifically IL-1α therapies for cancer, arthritis, and stroke, alongside an infectious disease pipeline. The company reported a net loss for 2025 and significant R&D spending, despite having received $750 million from a prior sale and returning $495 million to shareholders. XBiotech highlights its clinical trials for Natrunix in oncology and its Phase I completion for Hutrukin in neurology, while also outlining substantial operational and financial risks as a pre-market company without product revenue.
2026-02-25 11:51:51
This article provides a detailed financial overview of Xbiotech (XBIT), presenting its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2024. It highlights that Xbiotech is not profitable, reporting a net income of -$38.5M in FY2024, and notes weaknesses in its financial health with a Piotroski F-Score of 1/9 and low earnings quality. The report also details metrics like EBITDA, free cash flow, EPS, and R&D spending, alongside balance sheet items such as cash, assets, and liabilities.
2026-02-12 11:52:14
XBiotech Inc (XBIT) is currently considered undervalued based on its forward P/S ratio of 0.15 compared to its five-year average of 19.13. The article calculates a fair price range for XBIT between $815.99 and $816.78, significantly higher than its current price of $2.35. Despite this, XBIT's P/S ratio is significantly below the industry average, and its robust revenue growth is noted.
2025-12-19 11:09:00
XBiotech (NASDAQ:XBIT) shares have dropped below their 50-day moving average, trading as low as $2.40 with the last trade at $2.53 on Thursday. This comes with negative analyst sentiment, including a "sell (e+)" rating from Weiss Ratings and an overall "Sell" rating from MarketBeat data. Institutional investors hold approximately 55.7% of the company's stock, despite the negative P/E ratio and recent quarterly EPS of ($0.20).
